Hepatitis C virus: Evasion of the interferon-induced antiviral response

Journal of Molecular Medicine

Volumn 78, Issue 4, 2000, Pages 182-190

  Taylor, Deborah R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Hepatitis C virus; Interferon; PKR; Protein kinase; Signal transduction

Indexed keywords

DRUG RESPONSE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INFECTION; LIVER CELL CARCINOMA; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033934327     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000100     Document Type: Review

References (66)

1. 1. Di Bisceglie AM (1998) Hepatitis C. The Lancet 351:351-355
2. 2. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB (1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26:473-477
3. 3. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sonnerborg A, Weiland O (1998) Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87
4. 4. Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41-63
5. 5. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Matsumoto T, Hashimoto M, Kobayashi M, Kanda M, Morinaga T, et al (1995) Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 23:648-653
6. 6. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Isumi N, Marumo F, Sato C (1995) Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region J Clin Invest 96:224-230
7. 7. Rice CM (1996) Flaviviridae: the viruses and their replication In Fields BN (ed) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 931-959
8. 8. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner AJ, Lau JY, Choo QL, Chien D, Pileri P, Houghton M, Abrignani S (1996) A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells Proc Natl Acad Sci USA 93:1759-1763
9. 9. Zibert A, Schreier E, Roggendorf M (1995) Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653-661
10. 10. Kato N, Ootsuyama Y, Tanaka T, Nakagawa M, Muraiso K, Ohkoshi S, Hijikata M, Shimotohno K (1992) Marked sequence diversity in the putative envelope proteins of hepatitis C virus. Virus Res 22:107-123
11. 11. Cocquerel L, Meunier J-C, Pillez A, Wychowski C, Dubuisson J (1998) A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol 72: 2183-2191
12. 12. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C (1994) Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 75:1361-1369
13. 13. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins, JD, Corey L (1996) Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 70:7622-7631
14. 14. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S (1992) The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16: 619-624
15. 15. Tanji Y, Kaneko T, Satoh S, Shimotohno K (1995) Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 69:3980-3986
16. 16. Reed K, Xu J, Rice CM (1997) Phosphorylation of the hepatitis c virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J Virol 71:7187-7197
17. 17. Reed K, Rice CM (1999) Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. J Biol Chem 274:28011-28018
18. 18. Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kimura K, Shimotohno K (1994) Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun 205:320-326
19. 19. Asabe S, Tanji Y, Satoh S, Kaneko T, Kimura K, Shimotohno K (1997) The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation. J Virol 71:790-796
20. 20. Nedderman P, Clementi A, De Francesco R (1999) Hyper-phosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same protein. J Virol 73:9984-9991
21. 21. Enomoto N, Sato C (1995) Hepatitis C virus quasispecies populations during chronic hepatitis C infection. Trends Microbiol 3:445-447
22. 22. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81
23. 23. Herion D, Hoofnagle JH (1997) The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 25:769-770
24. 24. Kato N, Lan K-H, Ono-Nita SK, Shiratori Y, Omata M (1997) Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 71:8856-8859
25. 25. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB (1999) Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 80:1179-1183
26. 26. Tanimoto A, Ide Y, Arima N, Sasaguri Y, Padmanahban R (1997) The amino terminal deletion mutants of hepatitis C virus nonstructural prtein NS5A function as transcriptional activators in yeast. Biochem Biophys Res Commun 236:360-364
27. 27. Fukuma T, Enomoto N, Marumo F, Sato C (1998) Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology 28:1147-1153
28. 28. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, Eb F, Penin F, Wychowski C (1998) Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79: 1373-1381
29. 29. Samuel CE (1991) Antiviral actions of interferon: interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11
30. 30. Sen GC, Lengyel P (1992) The interferon system: a bird's eye view of its biochemistry. J Biol Chem 267:5017-5020
31. 31. Ivashkiv LB (1995) Cytokines and STATs: how can signals achieve specificity? Immunity 3:1-4
32. 32. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD (1994) Ligand-induced interferon gamma receptor tyrosine phosphorylation couples the receptor to its signal tranduction system (p91) EMBO J 13:1591-1600
33. 33. Gilmour KC, Reich NC (1995) Signal transduction and activation of gene transcription by interferons. Gene Expr 5:1-18
34. 34. Darnell JE, Kerr IM, Stark GR (1994) Jak-STAT pathway and transcriptional activation in response to IFNs and other extra-cellular signaling proteins. Science 264:1415-1421
35. 35. Darnell JE (1997) STATS and gene regulation. Science 277: 1630-1635
36. 36. Heim MH, Moradpour D, Blum HE (1999) Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 73:8469-8475
37. 37. Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56:727-777
38. 38. Castelli J, Wood KA, Youle RJ (1998) The 2-5A system in viral infection and apoptosis. Biomed Pharmacother 52:386-390
39. 39. Okuno T, Shindo M, Arai K, Matsumoto M, Takeda M Sokawa Y (1991) Determination of 2', 5'-oligoadenylate synthetase activity in acute non-A, non-B hepatitis patients, with special reference to histological outcome. In: Shikata T, Purcell RH, Uchida T (eds) Viral hepatitis C, D and E. Elsevier, Amsterdam, pp 133-135
40. 40. Karino Y, Hige S, Saga A, Sasaki Y, Tsuyuguchi M, Matsushima T, Miyazaki T, Okuuchi Y, Toyota J (1994) Relationship between serum 2-5AS activity and the reduction of HCV-RNA during interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda T (eds) Viral Hepatitis and Liver Disease. Springer, Tokyo, pp 631-634
41. 41. Pawlotsky J-M, Hovanessian A, Roudot-Thoraval F, Lebon P, Bouvier M, Babany G, Duval J, Dhumeaux D (1995) Activity of the interferon-induced 2', 5'-oligoadenylate synthetase in patients with chronic hepatitis C. J Interferon Cytokine Res 15:857-862
42. 42. Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garrucciu G, Diana MS (1993) Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 13:253-258
43. 43. Toda K, Kumagai N, Iwabuchi N Suzuki T, Saito H, Morizane T, Hibi T, Ishii H, Tsuchimoto K (1997) 2-5AS activity in serum and peripheral blood mononuclear cells for chronic active hepatitis C and the relationship to clinical outcome of interferon therapy (in Japanese). Nihon Rinsho Meneki Gakkai Kaishi 20:428-436
44. 44. Haller O, Frese M, Kochs G (1998) Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 17:220-230
45. 45. Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redailli A, Roffi L, Antonelli L, Pistello M, Dianzani F (1999) Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 19:243-251
46. 46. Taylor DR, Lee SB, Romano PR, Marshak DR, Hinnebusch AG, Esteban M, Mathews MB (1996) Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol Cell Biol 16:6295-6302
47. 47. Huang JT, Schneider RJ (1990) Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. Cell 65:271-280
48. I. Cell 44:391-400
49. 49. Proud CG (1995) PKR: a new name and new roles. Trends Biochem Sci 20:241-246
50. 50. Clemens MJ, Elia A (1997) The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17:503-524
51. 51. Mathews MB, Shenk T (1991) Adenovirus virus-associated RNA and translation control. J Virol 65:5657-5662
52. 52. Katze MG (1995) Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol 3:75-78
53. 53. Kostura M, Mathews MB (1989) Purification and activation of the double-stranded RNA-dependent eIF-2 kinase DAI. Mol Cell Biol 9:1576-1586
54. 54. Gale MJ, Blakely CM, Kwieciszewski B, Tan S-L, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18:5208-5218
55. 55. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C (1999) Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30:1045-1053
56. 56. Gale MJ, Korth MJ, Tang NM, Tan S-L, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227
57. 57. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110
58. 58. Polyak SJ, Paschal DM, McArdle S, Gale MJ, Moradpour D, Gretch DR (1999) Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 29:1262-1271
59. 59. Gale M, Kwieciszewski B, Dossett M, Nakao H, Katze MG (1999) Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 73:6506-6516
60. 60. Nakano I, Fukuda Y, Katano Y, Nakano S, Kumada T, Hayakawa T (1999) Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? J Hepatol 30: 1014-1022
61. 61. Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG (1999) NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 96:5533-5538
62. 62. Tamm I, Lin SL, Pfeffer LM, Seghal PB (1987) Interferons alpha and beta as cell regulatory molecules. Interferon 9: 14-74
63. 63. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185
64. 64. David M, Wong L, Flavell R, Thompson SA, Wells A, Larner AC, Johnson GR (1996) The SH2 domain-containing tyrosine phosphatase PTP 1D is required for interferon alpha/beta-induced gene expression. J Biol Chem 271:9185-9188
65. 65. Carroll MP, Peterson DJ, May WS (1993) Interferon α and transformation growth factor β rapidly block hematopoietic growth factor-induced Raf-1 phosphorylation. Blood 82 [Suppl 1]:371A
66. 66. Zhou A, Paranjape JM, Der SD, Williams BR, Silverman RH (1999) Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 258: 435-440